

Dmitry Soloviev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3029350/publications.pdf>

Version: 2024-02-01

32
papers

2,186
citations

394421

19
h-index

434195

31
g-index

33
all docs

33
docs citations

33
times ranked

4239
citing authors

#	ARTICLE	IF	CITATIONS
1	¹⁸ F-C2Am: a targeted imaging agent for detecting tumor cell death in vivo using positron emission tomography. EJNMMI Research, 2020, 10, 151.	2.5	7
2	[¹⁸ F]fluoroethyltyrosine-induced Cerenkov Luminescence Improves Image-Guided Surgical Resection of Glioma. Theranostics, 2018, 8, 3991-4002.	10.0	19
3	Rapid Imaging of Tumor Cell Death In Vivo Using the C2A Domain of Synaptotagmin-I. Journal of Nuclear Medicine, 2017, 58, 881-887.	5.0	24
4	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	27.6	792
5	Preclinical Applications of 3'-Deoxy-3'-[¹⁸ F] Fluoro-thymidine in Oncology - A Systematic Review. Theranostics, 2017, 7, 40-50.	10.0	32
6	Abstract 1869: Improved image-guided surgical resection of glioblastoma with [¹⁸ F]-fluoroethyltyrosine Cerenkov luminescence imaging. , 2017, , .		0
7	The relationship between endogenous thymidine concentrations and [¹⁸ F]FLT uptake in a range of preclinical tumour models. EJNMMI Research, 2016, 6, 63.	2.5	11
8	Prospective study evaluating the relative sensitivity of ¹⁸ F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and ^{99m} Tc-MDP bone scintigraphy, using an adaptive trial design. Annals of Oncology, 2015, 26, 2113-2118.	1.2	59
9	Imaging Tumor Metabolism Using Positron Emission Tomography. Cancer Journal (Sudbury, Mass), 2015, 21, 129-136.	2.0	41
10	Dual-modality gene reporter for in vivo imaging. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 415-420.	7.1	91
11	Late Imaging with [¹¹ C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET. Journal of Nuclear Medicine, 2014, 55, 1144-1149.	5.0	24
12	509 THERAPEUTIC FATTY ACID SYNTHASE INHIBITION IN PROSTATE CANCER AND THE USE OF ¹¹ C-ACETATE TO MONITOR THERAPEUTIC EFFECTS. Journal of Urology, 2013, 189, .	0.4	4
13	Evaluation of the Sensitivity and Specificity of ¹¹ C-Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn's Adenomas. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 100-109.	3.6	203
14	[¹⁸ F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment. European Journal of Cancer, 2012, 48, 416-424.	2.8	78
15	Neuro-Oncology Single-Photon Emission CT: A Current Overview. Neurographics, 2011, 1, 108-120.	0.1	6
16	Hyperpolarized ¹³ C MRI and PET: In Vivo Tumor Biochemistry. Journal of Nuclear Medicine, 2011, 52, 1333-1336.	5.0	52
17	PET imaging with ¹¹ C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 942-9.	6.4	35
18	¹⁸ F-â€œcholine and/or ¹¹ C-â€œacetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostateâ€œspecific antigen values ($\leq 1\text{ ng/mL}$) after radical prostatectomy. BJU International, 2007, 99, 1415-1420.	2.5	190

#	ARTICLE	IF	CITATIONS
19	¹¹ C-acetate PET in the early evaluation of prostate cancer recurrence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 185-196.	6.4	139
20	Captive solvent [¹¹ C]acetate synthesis in GMP conditions. <i>Applied Radiation and Isotopes</i> , 2006, 64, 995-1000.	1.5	28
21	Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using ¹⁴⁹ Tb-rituximab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 547-554.	6.4	93
22	Preparation of [¹¹ C] radioligands with high specific radioactivity on a commercial PET tracer synthesizer. <i>Nuclear Medicine and Biology</i> , 2003, 30, 79-83.	0.6	25
23	Production routes of the alpha emitting ¹⁴⁹ Tb for medical application. <i>Radiochimica Acta</i> , 2002, 90, 247-252.	1.2	59
24	Automation of [¹¹ C]acyl chloride syntheses using commercially available ¹¹ C-modules. <i>Applied Radiation and Isotopes</i> , 2002, 57, 675-679.	1.5	17
25	Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[¹¹ C]bisoprolol, a putative $\hat{2}1$ -selective adrenoceptor radioligand. <i>Neurochemistry International</i> , 2001, 38, 169-180.	3.8	32
26	Labeling and Evaluation of N-[¹¹ C]Methylated Quinoline-2-carboxamides as Potential Radioligands for Visualization of Peripheral Benzodiazepine Receptors. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 579-585.	6.4	56
27	Synthesis and in vivo evaluation of 3-[¹¹ C]methyl-(3-methoxy-naphthalen)-2-yl-(1-benzyl-piperidin)-4-yl-acetate (SB-235753), as a putative dopamine D4 receptors antagonist for PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2000, 43, 359-374.	1.0	12
28	Synthesis and in vivo evaluation of [¹¹ C]ICI 118551 as a putative subtype selective $\hat{2}2$ -adrenergic radioligand. <i>International Journal of Pharmaceutics</i> , 2000, 204, 101-109.	5.2	15
29	Evaluation of [O-methyl- ¹¹ C]fluvoxamine as a tracer for serotonin re-uptake sites. <i>Nuclear Medicine and Biology</i> , 2000, 27, 177-181.	0.6	5
30	High yield synthesis of [¹¹ C]-acetone through selective quenching of methyl lithium. <i>Nuclear Medicine and Biology</i> , 1999, 26, 431-435.	0.6	17
31	Synthesis and Biodistribution of (R,S)-[O-Methyl- ¹¹ C]-1-[3-(5-Methoxy-1,2,3,4-tetrahydro-1-naphthalenyl)propyl]-4-Phenylpiperazine (PNU-157760), A Putative Radioligand for 5-HT _{1A} Receptors. <i>Bioorganic Chemistry</i> , 1998, 26, 91-102.	4.1	11
32	Synthesis of [O-methyl- ¹¹ C]fluvoxamine as a potential serotonin uptake site radioligand. <i>Applied Radiation and Isotopes</i> , 1997, 48, 749-754.	1.5	9